Lupin receives EIR from USFDA for Goa facility

27 Feb 2026 Evaluate

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its facility in Goa, India, with a satisfactory Voluntary Action Indicated (VAI) classification. The EIR was issued following an inspection of the facility from November 10 to November 21, 2025.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2301.35 -21.85 (-0.94%)
27-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1738.10
Dr. Reddys Lab 1287.20
Cipla 1347.65
Zydus Lifesciences 922.50
Lupin 2301.35
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×